AACR 2024 | Which mutations benefit most from PARP inhibitors in prostate cancer?

Hannah McManus, MD, Duke Cancer Institute, Duke University School of Medicine, Durham, NC, comments on which groups of patients with prostate cancer benefit the most from PARP inhibitors. Whilst different mutations may respond differently to PARP inhibitors, BRCA1/2-mutant prostate cancer seems to respond the best from PARP inhibitors. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.